Patent ID: 8633173

Claim:
A method of treating cancer by inhibiting JAK2, comprising administering to a subject in recognized need thereof a compound of Formula V: or a salt thereof, wherein: R 3A , R 4A , and R 5A are each independently selected from H, OH, CN, NO 2 , halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )alkoxy, halo(C 1 -C 4 )alkyl, and halo(C 1 -C 4 )alkoxy; R 7A is selected from H and (C 1 -C 8 )alkyl; R 8 is selected from SO 2 R 7A , NR 7A COR 7A , (C 2 -C 8 )alkyl, (C 1 -C 8 )alkoxy, halo(C 2 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, (C 3 -C 14 )cycloalkyl, (C 3 -C 14 )cycloalkyloxy, (C 3 -C 14 )cycloalkyl(C 1 -C 4 )alkyl, (C 3 -C 14 )cycloalkyl(C 1 -C 4 )alkoxy, (C 6 -C 10 )aryl, (C 6 -C 10 )aryloxy, (C 6 -C 10 )aryl(C 1 -C 4 )alkyl, (C 6 -C 10 )aryl(C 1 -C 4 )alkoxy, (C 2 -C 14 )heterocycloalkyl, (C 2 -C 14 )heterocycloalkyloxy, (C 2 -C 14 )heterocycloalkyl(C 1 -C 4 )alkyl, (C 2 -C 14 )heterocycloalkyl(C 1 -C 4 )alkoxy, (C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryloxy, (C 2 -C 9 )heteroaryl(C 1 -C 4 )alkyl, and (C 2 -C 9 )heteroaryl(C 1 -C 4 )alkoxy, wherein each of the aforementioned groups may be optionally substituted with between one to four substituents; R 9 is selected from SO 2 R 7A , POR 7A R 7A , NR 7A SO 2 R 7A , halo(C 1 -C 4 )alkyl, halogen, or (C 2 -C 14 )heterocycloalkyl optionally substituted with between one to four substituents; R 10 is selected from H and (C 1 -C 4 )alkyl optionally substituted with SO 2 (C 1 -C 4 )alkyl; g is selected from 0, 1, 2, or 3; and wherein said optional substituents are each independently selected from OH, CN, oxo, NO 2 , halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )alkoxy, hydroxy(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, (C 3 -C 14 )cycloalkyl, (C 3 -C 14 )cycloalkyl(C 1 -C 4 )alkyl, (C 3 -C 14 )cycloalkyloxy, (C 3 -C 14 )cycloalkyl(C 1 -C 4 )alkoxy, NR 7A R 7A , (C 1 -C 4 )alkyl-NR 7A R 7A , (C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 1 -C 4 )alkyl, (C 6 -C 10 )aryloxy, (C 6 -C 10 )aryl(C 1 -C 4 )alkoxy, SO 2 R 7A , (C 1 -C 4 )alkyl-SO 2 R 7A , (C 1 -C 4 )alkyl-C(O)NR 7A R 7A , C(O)NR 7A R 7A , (C 1 -C 4 )alkyl-SO 2 NR 7A R 7A , SO 2 NR 7A R 7A , (C 2 -C 14 )heterocycloalkyl, (C 2 -C 14 )heterocycloalkyloxy, (C 2 -C 14 )heterocycloalkyl(C 1 -C 4 )alkyl, (C 2 -C 14 )heterocycloalkyl(C 1 -C 4 )alkoxy, (C 2 -C 9 )heteroaryl, (C 2 -C 9 )heteroaryloxy, (C 2 -C 9 )heteroaryl(C 1 -C 4 )alkyl, (C 2 -C 9 )heteroaryl(C 1 -C 4 )alkoxy, COR 7A , (C 1 -C 4 )alkyl-COR 7A , NR 7A COR 7A , (C 1 -C 4 )alkyl-NR 7A COR 7A , NR 7A SO 2 R 7A , (C 1 -C 4 )alkyl-NR 7A SO 2 R 7A , OSO 2 R 7A , (C 1 -C 4 )alkyl-OSO 2 R 7A , POR 7A R 7A , (C 1 -C 4 )alkyl-POR 7A R 7A , CO 2 R 7A or (C 1 -C 4 )alkyl-CO 2 R 7A , wherein said compound or salt thereof preferentially inhibits the JAK2 enzyme in vitro.